Rhythm Pharmaceuticals, Inc. revenue
Rhythm Pharmaceuticals, Inc.'s revenue was $190m in fiscal 2025, up 45.8% on the year before. Since fiscal 2021 ($3.2m) it has grown at a compound 178.5% a year. Over the last twelve months it was $240m.
Revenue history
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 3 | 24 | 77 | 130 | 190 | 240 |
| Growth on the year before | — | — | — | — | — | — | +649.5% | +227.6% | +68.1% | +45.8% | — |
| Gross profit | — | — | — | — | — | 3 | 22 | 68 | 117 | 170 | 214 |
| Gross margin | — | — | — | — | — | 81.0% | 91.0% | 88.0% | 89.7% | 89.7% | 89.0% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $195M | 102.6% | ▲ 49.7% |
| Licenses | -$5M | -2.6% | — |
From Rhythm Pharmaceuticals, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. | $240m | 53.5% | 76.3% |
| Anaptysbio, Inc | $238m | 92.9% | 163.9% |
| Ideaya Biosciences, Inc. | $234m | -70.1% | 94.0% |
| Puma Biotechnology, Inc. | $231m | -2.9% | 0.2% |
| Ligand Pharmaceuticals Inc | $254m | 1.0% | 18.2% |
| Akebia Therapeutics, Inc. | $219m | 7.5% | 2.9% |
Compare with peers
- Anaptysbio, Inc revenue
- Ideaya Biosciences, Inc. revenue
- Puma Biotechnology, Inc. revenue
- Ligand Pharmaceuticals Inc revenue
- Akebia Therapeutics, Inc. revenue
Head to head: ANAB vs RYTMIDYA vs RYTMPBYI vs RYTMLGND vs RYTM
More: Biotechnology stocks compared, Health Care sector, rankings of US companies